Dmytro Kharkov

NeuroPace Inc introduces RNS System as alternative for patients unresponsive to epilepsy medications

NeuroPace Inc introduces RNS System as alternative for patients unresponsive to epilepsy medications
NeuroPace Inc promotes RNS System

NeuroPace Inc is drawing attention to the estimated 1 million Americans living with drug-resistant epilepsy, particularly those who have failed to control seizures with two or more medications.

The company is promoting its RNS System as a potential solution for individuals who have not found relief through conventional drug therapies. Information about the RNS System and its safety is available through official channels, reflecting heightened efforts to address unmet needs in epilepsy management.

NeuroPace has previously encouraged patients with uncontrolled seizures to assess whether they are candidates for the RNS System through an online suitability quiz. In April, the company released findings from the NAUTILUS Study detailing advances in neuromodulation for drug-resistant idiopathic generalized epilepsy. These efforts follow continued outreach to address gaps in epilepsy care.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.